News Releases News Releases Year None2022202120202019201820172016 Apr 25, 2022 Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern Apr 25, 2022 Dr. Henry Ji, Sorrento Therapeutics’ Chairman and CEO and Scilex Holding Company’s Executive Chairman, to Present at the B. Riley Securities’ 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022) Apr 12, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill Apr 04, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022 Mar 31, 2022 Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19 Mar 25, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Mar 20, 2022 Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants Mar 18, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for Mar 17, 2022 Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I Mar 02, 2022 Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Next page next › Last page last » Tools Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
News Releases Year None2022202120202019201820172016 Apr 25, 2022 Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern Apr 25, 2022 Dr. Henry Ji, Sorrento Therapeutics’ Chairman and CEO and Scilex Holding Company’s Executive Chairman, to Present at the B. Riley Securities’ 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022) Apr 12, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill Apr 04, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022 Mar 31, 2022 Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19 Mar 25, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Mar 20, 2022 Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants Mar 18, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for Mar 17, 2022 Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I Mar 02, 2022 Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Next page next › Last page last »
Apr 25, 2022 Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern
Apr 25, 2022 Dr. Henry Ji, Sorrento Therapeutics’ Chairman and CEO and Scilex Holding Company’s Executive Chairman, to Present at the B. Riley Securities’ 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022)
Apr 12, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill
Apr 04, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022
Mar 31, 2022 Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19
Mar 25, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage
Mar 20, 2022 Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants
Mar 18, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for
Mar 17, 2022 Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I
Mar 02, 2022 Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure
